Lb Pharmaceuticals (LBRX) Total Liabilities (2024 - 2026)

Lb Pharmaceuticals has reported Total Liabilities for 3 years, with the latest figure at $14.8 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities fell 85.11% year-over-year to $14.8 million; the trailing twelve-month figure through Mar 2026 stood at $14.8 million (down 85.11% YoY), and the FY2025 full-year result was $11.6 million, down 15.94% from the prior year.
• Total Liabilities for Q1 2026 stood at $14.8 million, up from $11.6 million in the prior quarter.
• The five-year high for Total Liabilities was $99.3 million in Q1 2025, with the low at $10.5 million in Q3 2025.
• Average Total Liabilities over 3 years is $40.3 million, with a median of $14.3 million recorded in 2024.
• Peak annual rise in Total Liabilities reached 15.94% in 2025, while the deepest fall reached 88.49% in 2025.
• Tracing LBRX's Total Liabilities over 3 years: stood at $13.8 million in 2024, then slipped by 15.94% to $11.6 million in 2025, then increased by 27.23% to $14.8 million in 2026.
• The last three Total Liabilities figures came in at $14.8 million (Q1 2026), $11.6 million (Q4 2025), and $10.5 million (Q3 2025), per Business Quant data.

Peer Comparison